1-5 of 5
James Capobianchi
Close
Sort by
Journal Articles

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

Clinical Trials & Observations
Vijay G. Bhoj, Dimitrios Arhontoulis, Gerald Wertheim, James Capobianchi, Colleen A. Callahan, Christoph T. Ellebrecht, Amrom E. Obstfeld, Simon F. Lacey, Jan J. Melenhorst, Farzana Nazimuddin, Wei-Ting Hwang, Shannon L. Maude, Mariusz A. Wasik, Adam Bagg, Stephen Schuster, Michael D. Feldman, David L. Porter, Stephen A. Grupp, Carl H. June, Michael C. Milone
Journal: Blood
Blood (2016) 128 (3): 360–370.
https://doi.org/10.1182/blood-2016-01-694356
Published: 2016
Includes: Supplemental data
Journal Articles

Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy

Vijay Bhoj, MD PhD, Michael C Milone, MD PhD, Carl H. June, MD, David Porter, MD, Stephan A. Grupp, MD PhD, Jan J Melenhorst, PhD, Simon F. Lacey, PhD BSc, Colleen Callahan, MSN, CRNP, James Capobianchi, Gerald Wertheim, MDPhD, Yolanda Mahnke, PhD
Journal: Blood
Blood (2014) 124 (21): 1110.
https://doi.org/10.1182/blood.V124.21.1110.1110
Published: 2014
Journal Articles

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

David L. Porter, MD, Noelle V. Frey, MDMS, J. Joseph Melenhorst, PhD, Wei-Ting Hwang, PhD, Simon F. Lacey, PhD BSc, Pamela Shaw, PhD, Anne Chew, PhD, Stephan A. Grupp, MD PhD, James Capobianchi, Joan Gilmore, Michael Kalos, PhD, Manuel Litchman, MD, Lester Lledo, RN,MSN,CNP, Alison Wakoff Loren, MDMS, Yolanda Mahnke, PhD, Katherine T. Marcucci, PhD, Holly McConville, RN, Angela Shen, MD, Patricia A. Wood, MD PhD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD
Journal: Blood
Blood (2014) 124 (21): 1982.
https://doi.org/10.1182/blood.V124.21.1982.1982
Published: 2014
Journal Articles

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

David L. Porter, MD, Michael Kalos, PhD, Noelle V. Frey, MD, Stephan A. Grupp, MD, PhD, Alison W. Loren, MD, Christina Jemison, RN, Joan Gilmore, Holly McConville, RN, BSN, James Capobianchi, Lester Lledo, CRNP, Anne Chew, PhD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD
Journal: Blood
Blood (2013) 122 (21): 4162.
https://doi.org/10.1182/blood.V122.21.4162.4162
Published: 2013
Journal Articles

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

David L. Porter, MD, Michael Kalos, PhD, Noelle V. Frey, MD, Stephan A Grupp, MD, PhD, Alison W. Loren, MD, Christina Jemision, RN, Joan Gilmore, Holly McConville, RN, BSN, James Capobianchi, Lester Lledo, CRNP, Anne Chew, PhD, Angela Shen, MD, Patricia A. Wood, MD, PhD, Manuel Litchman, MD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD
Journal: Blood
Blood (2013) 122 (21): 873.
https://doi.org/10.1182/blood.V122.21.873.873
Published: 2013